Gunhild M. Mælandsmo

1963 -

country of citizenship: Norway

educated at: University of Oslo

occupation: researcher, professor

award received: Dr. Mørks Legats pris

Series

There is nothing here

Create a new serie

Works

There is nothing here

Create a new work

Articles 180

Date

Title

Authors

2022-03-24

AXL inhibition improves BRAF-targeted treatment in melanoma

Gunhild M. Mælandsmo
2021-05-25

MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro

Suvi-Katri Leivonen, Gunhild M. Mælandsmo
2021-05-01

Detection of phenotype-specific therapeutic vulnerabilities in breast cells using a CRISPR loss-of-function screen

Clint A Stalnecker, Siver Andreas Moestue, Gunhild M. Mælandsmo, Olav Engebraaten, Anna Barkovskaya, Kotryna Seip, Bylgja Hilmarsdottir, Lina Prasmickaite
2021-10-06

Novel human melanoma brain metastasis models in athymic nude fox1<sup>nu</sup> mice: Site-specific metastasis patterns reflecting their clinical origin

Torstein R. Meling, Jens Pahnke, Gunhild M. Mælandsmo
2021-09-17

Argininosuccinate lyase is a metabolic vulnerability in breast development and cancer

Siver Andreas Moestue, Gunhild M. Mælandsmo, Óttar Rolfsson, Bylgja Hilmarsdottir
2021-06-04

EMT-Derived Alterations in Glutamine Metabolism Sensitize Mesenchymal Breast Cells to mTOR Inhibition

Maria Tunset Grinde, Gunhild M. Mælandsmo, Óttar Rolfsson
2020-03-05

Drug-Loaded Photosensitizer-Chitosan Nanoparticles for Combinatorial Chemo- and Photodynamic-Therapy of Cancer

Priyanka Sahariah, Már Másson, Tore-Geir Iversen, Gunhild M. Mælandsmo, Anders Høgset, Tore Skotland, Anders Øverbye, Kirsten Sandvig, Abhilash D Pandya
2020-03-18

ECM1 secreted by HER2-overexpressing breast cancer cells promotes formation of a vascular niche accelerating cancer cell migration and invasion

Gunhild M. Mælandsmo
2020-03-25

Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study

Anne Hansen Ree, Kjetil Boye, Svein Dueland, Marius Lund-Iversen, Kjersti Flatmark, Anne-Lise Børresen-Dale, Eivind Hovig, Sigve Nakken, Ole Christian Lingjærde, Vessela Kristensen, Gunhild M. Mælandsmo, Hege G. Russnes, Vigdis Nygaard, Vegard Nygaard, Christin Johansen, Klaus Beiske, Lars Julsrud, Claudius H Reisse, Gry A Geitvik, Inger Riise Bergheim, Anne Negård, Vivi Ann Flørenes
2020-01-09

Soluble AXL as a marker of disease progression and survival in melanoma

Karine Flem-Karlsen, Marta Nyakas, Gunhild M. Mælandsmo
2020-01-28

The expression of the long NEAT1_2 isoform is associated with human epidermal growth factor receptor 2-positive breast cancers

Erik Knutsen, Therese Sørlie, Silje H. Nordgard, Gunhild M. Mælandsmo
2020-04-01

Physicochemical Characterization, Toxicity and In Vivo Biodistribution Studies of a Discoidal, Lipid-Based Drug Delivery Vehicle: Lipodisq Nanoparticles Containing Doxorubicin

Gunhild M. Mælandsmo, Tore Skotland, Kirsten Sandvig, Maria Lyngaas Torgersen, Abhilash D Pandya
2020-11-25

Protein Kinase C Isozymes Associated With Relapse Free Survival in Non-Small Cell Lung Cancer Patients

Gunhild M. Mælandsmo
2019-01-22

Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model

Gunhild M. Mælandsmo, Gunnar Kvalheim
2019-05-14

Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer

Maria Tunset Grinde, Hanna Maja Tunset, Siver Andreas Moestue, Gunhild M. Mælandsmo, Mads H Haugen, Bylgja Hilmarsdottir, Jana Kim
2019-05-13

A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases

Kjersti Flatmark, Gunhild M. Mælandsmo, Anne Hansen Ree, Karianne Giller Fleten, Vigdis Nygaard, Vivi Ann Flørenes, Inger Riise Bergheim
2019-04-09

p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance

Karine Flem-Karlsen, Caroline E Nunes-Xavier, Gunhild M. Mælandsmo
2019-04-05

O-GlcNAc Transferase Inhibition Differentially Affects Breast Cancer Subtypes

Siver Andreas Moestue, Harri Itkonen, Gunhild M. Mælandsmo, Anna Barkovskaya, Kotryna Seip, Bylgja Hilmarsdottir
2019-02-25

Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain

Anne Hansen Ree, Eivind Hovig, Anne-Lise Børresen-Dale, Kjersti Flatmark, Gunhild M. Mælandsmo, Hege G. Russnes, Vigdis Nygaard, Vegard Nygaard, Christin Johansen, Klaus Beiske, Inger Riise Bergheim, Anne Negård
2019-03-21

Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma

Marta Nyakas, Pål Aukrust, Thor Ueland, Arne Yndestad, Bente Halvorsen, Gunhild M. Mælandsmo
2019-12-23

Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma

Karine Flem-Karlsen, Mads H Haugen, Gunhild M. Mælandsmo
2019-12-04

Spheroid-Derived Cells From Renal Adenocarcinoma Have Low Telomerase Activity and High Stem-Like and Invasive Characteristics

Gunhild M. Mælandsmo
2019-08-15

Design, synthesis and biological evaluation of 6-substituted quinolines derived from cabozantinib as c-Met inhibitors

Vegard Torp Lien, Gunhild M. Mælandsmo
2019-10-08

Serum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers

Xavier Tekpli, Pål Aukrust, Thor Ueland, Arne Yndestad, Bente Halvorsen, Elin Faye Borgen, Vessela Kristensen, Olav Engebraaten, Gunhild M. Mælandsmo, Kristin A Taskén, Guro F. Giskeødegård
2019-08-06

Paclitaxel-loaded biodegradable ROS-sensitive nanoparticles for cancer therapy

Abhilash D Pandya, Martin Hrubý, Gunhild M. Mælandsmo, Tore Skotland, Kirsten Sandvig
2018-05-01

Enhanced targeting of triple-negative breast carcinoma and malignant melanoma by photochemical internalization of CSPG4-targeting immunotoxins

Pål Kristian Selbo, Marius Strømbo Eng, Anette Weyergang, Gunhild M. Mælandsmo, Anders Høgset, Kristian Berg
2018-09

Basal-like breast cancer engages tumor-supportive macrophages via secreted factors induced by extracellular S100A4

Anne-Lise Børresen-Dale, Vessela Kristensen, Gunhild M. Mælandsmo, Silje H. Nordgard, Shakila Jabeen, Mads H Haugen, Olav Engebråten, Lina Prasmickaite
2018-07-13

Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease.

Åslaug Helland, Bente Halvorsen, Arne Yndestad, Thor Ueland, Pål Aukrust, Odd Terje Brustugun, Gunhild M. Mælandsmo, May-Bente Bengtson, Kristin A Taskén
2018-12-04

Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft

Abhilash D Pandya, Kjersti Flatmark, Sofie Snipstad, Olav Engebraaten, Gunhild M. Mælandsmo, Tore Skotland, Tore-Geir Iversen, Anders Øverbye, Kirsten Sandvig, Karianne Giller Fleten
2018-09-18

Stroma-induced phenotypic plasticity offers phenotype-specific targeting to improve melanoma treatment

Philippe Lucarelli, Olav Engebraaten, Gunhild M. Mælandsmo
2017-07-18

Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases.

Åsmund Avdem Fretland, Anne-Lise Børresen-Dale, Laxmi Silwal-Pandit, Kjersti Flatmark, Gunhild M. Mælandsmo, Anne Hansen Ree, Olga Østrup, Veronica Skarpeteig, Krzysztof Grzyb, Vigdis Nygaard, Audun E Berstad
2017-08-12

Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide.

Kirsten Sandvig, Kjersti Flatmark, Gunhild M. Mælandsmo, Olav Engebraaten, Tore Skotland, Tore-Geir Iversen, Anders Øverbye

Human - wd:Q76257274

Welcome to Inventaire

the library of your friends and communities

learn more